SCHEMBL25848983

SCHEMBL25848983

COCCS(=O)(=O)c1ccc(C(=O)NCc2ccc(C(F)(F)F)cc2)s1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.50
HDAC1 Q13547 3/20 0.50
HDAC4 P56524 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
LSS P48449 1/20 0.46
PPARA Q07869 12/20 0.45
PPARG P37231 5/20 0.44
EPHX2 P34913 2/20 0.44
MAPK14 Q16539 1/20 0.44
PPARD Q03181 3/20 0.44
PSEN1 P49768 2/20 0.42
PSEN2 P49810 2/20 0.42
APH1B Q8WW43 2/20 0.42
NCSTN Q92542 2/20 0.42
APH1A Q96BI3 2/20 0.42
PSENEN Q9NZ42 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848867 0.92 HDAC3 (0.49) HDAC3HDAC1HDAC4HDAC6PPARA
SCHEMBL24196677 0.89 LSS (0.49) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL25848934 0.85 PPARA (0.48) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL25848940 0.85 LSS (0.50) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL25849324 0.83 PPARA (0.49) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL24196673 0.83 PPARA (0.42) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL24196671 0.82 PPARA (0.49) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL25848863 0.81 HDAC1 (0.47) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL24196675 0.79 MAPK14 (0.45) HDAC3HDAC1HDAC4HDAC6LSS
SCHEMBL25848978 0.78 HDAC3 (0.50) HDAC3HDAC1HDAC4HDAC6LSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 HDAC3 1223/4885HDAC1 1680/4885HDAC4 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.